116285-51-9

Upstream product

• 3166-54-9 2-(chloromethyl)-3-(2-methylphenyl)-3H-quinazoline-4-one 
• 94-09-7 p-aminoethylbenzoate 
• 116270-54-3 2-<(p-Hydrazinocarbonyl)phenylaminomethyl>-3-(o-tolyl)quinazolin-4(3H)-one 
• 622-59-3 1-isothiocyanato-4-methylbenzene 

Downstream Products

• 116270-72-5 3-o-Tolyl-2-{[4-(5-p-tolylamino-[1,3,4]thiadiazol-2-yl)-phenylamino]-methyl}-3H-quinazolin-4-one 
• 116270-86-1 3-o-Tolyl-2-{[4-(5-p-tolylamino-[1,3,4]oxadiazol-2-yl)-phenylamino]-methyl}-3H-quinazolin-4-one 

Relevant academic research and scientific papers

Synthesis and Pharmacological Evaluation of N1--N4-arylthiosemicarbazides and 2-Arylamino-5--1,3,4-thiadiazoles/oxadiazoles as Oral Hypoglycemic Agents

A series of 2-arylamino-5--1,3,4-thiadiazoles/oxadiazoles (III/IV) have been synthesised from N1--N4-arylthiosemicarbazides (II) by treatment with conc. sulphuric acid or mercuric oxide.The thiosemicarbazides (II), in turn, have been prepared by refluxing 2--3-arylquinazolin-4(3H)-one (I) with various aryl isothiocyanates in abs. ethanol.A few of these compounds when tested on rats at an oral dose of 250 mg/kg, reduced the blood sugar to about 25 percent.